Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, ...
AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, will present the first clinical data from ...
On Target is a new recurring feature from STAT that dives deep into the most promising drug targets in oncology. Of all the wily ways tumors have to turn back attacks from therapies or the immune ...
For years, scientists have thought that TGF-Beta, a signaling protein that holds sway over an astonishing array of cellular processes from embryonic development to cancer, could only do its work once ...
On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd.
Please provide your email address to receive an email when new articles are posted on . Transforming growth factor beta mutation biomarkers may help identify patients at high risk for cancer of the ...
The physical changes that occur in the brain of patients with Alzheimer's disease (AD), the most common cause of dementia in the elderly, have been well characterized, but the cause(s) of this disease ...
Scientists from IRB and CNAG have identified the mechanisms that prevent defensive cells from attacking the tumor and propose ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback